4-(Propan-2-YL)-9H-fluoren-9-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 4-(Propan-2-YL)-9H-fluoren-9-one
• 英文别名: 4-propan-2-ylfluoren-9-one
• 化学式: C₁₆H₁₄O
• mdl: MFCD00441917
• 分子量: 222.28
• InChiKey: NFFUOFUNUJZWDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• GLYCOPEPTIDE ANTIBIOTIC MONOMER DERIVATIVES
  申请人：National University Corporation Nagoya University

  公开号：EP1818340A1

  公开（公告）日：2007-08-15

  Novel glycopeptide antibiotic derivatives. These derivatives are represented by the formula (aglycon part of glycopeptide antibiotic derivative)-(Sac-NH)-RA [wherein (aglycon part of glycopeptide antibiotic derivative) is the part formed by removing the sugar part from a known glycopeptide antibiotic derivative; (Sac-NH) part is an amino sugar part or a sugar chain part containing an amino sugar; and RA represents, e.g., the formula -X1-Ar1-X2-Y-X3-Ar2 (wherein X1, X2, and X3 each represents 1) a single bond or 2) a heteroatom or heteroatom-containing group selected from the group consisting of -N=, =N-, -NR1-, -O-, etc.; Y represents -NR2CO- or -CONR2- (wherein R2 represents hydrogen or lower alkyl), etc.)]. These derivatives have antibacterial activity against vancomycin-resistant bacteria.

  新型糖肽抗生素衍生物。这些衍生物由式（糖肽抗生素衍生物的苷元部分）-(Sac-NH)-RA 表示[其中，（糖肽抗生素衍生物的苷元部分）是从已知的糖肽抗生素衍生物中去除糖部分而形成的部分；(Sac-NH)部分是氨基糖部分或含有氨基糖的糖链部分；RA 表示，例如、式-X1-Ar1-X2-Y-X3-Ar2（其中 X1、X2 和 X3 各自代表 1）单键或 2）选自-N=、=N-、-NR1-、-O-等组成的杂原子或含杂原子的基团；Y 代表-NR2CO-或-CONR2-（其中 R2 代表氢或低级烷基）等）]。这些衍生物对耐万古霉素细菌具有抗菌活性。
• Glycopeptide Antibiotic Monomer Derivatives
  申请人：Arimoto Hirokazu

  公开号：US20080097078A1

  公开（公告）日：2008-04-24

  Novel glycopeptide antibiotic derivatives. These derivatives are represented by the formula (aglycon part of glycopeptide antibiotic derivative)-(Sac-NH)—R A [wherein (aglycon part of glycopeptide antibiotic derivative) is the part formed by removing the sugar part from a known glycopeptide antibiotic derivative; (Sac-NH) part is an amino sugar part or a sugar chain part containing an amino sugar; and R A represents, e.g., the formula —X 1 —Ar 1 —X 2 —Y—X 3 —Ar 2 (wherein X 1 , X 2 , and X 3 each represents 1) a single bond or 2) a heteroatom or heteroatom-containing group selected from the group consisting of —N═, ═N—, —NR 1 —, —O—, etc.; Y represents —NR 2 CO— or —CONR 2 — (wherein R 2 represents hydrogen or lower alkyl), etc.)]. These derivatives have antibacterial activity against vancomycin-resistant bacteria.
• DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST
  申请人：Janssen Pharmaceutica NV

  公开号：US20180028660A1

  公开（公告）日：2018-02-01

  The present invention relates to combinations of a DGAT inhibitor and a peroxisome proliferator-activator receptor (PPAR) agonist or a prodrug thereof. The invention further relates to methods for preparing such combinations, pharmaceutical compositions comprising said combinations as well as the use as a medicament of said combinations. The present invention also relates to novel DGAT inhibitors. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicament of said compounds.
• US8778874B2
  申请人：——

  公开号：US8778874B2

  公开（公告）日：2014-07-15